Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of RC1416 Injection in Adult Patients With Moderate to Severe Asthma

NCT07403487 is registered in ClinicalTrials.gov with Nanjing RegeneCore Biotech Co., Ltd. as lead sponsor.

NCT NCT07403487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07403487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of RC1416 Injection in Adult Patients With Moderate to Severe Asthma
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 10, 2026
Completion date
February 28, 2028
Enrollment
195 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe asthma